- Baiyunshan’s net income in the first quarter was 1.96 billion yuan. This is an increase from the previous 1.91 billion yuan in the same period last year.
- The increase in net income is a growth of 2.5% compared to the same period last year.
- Revenue for the period was 22.95 billion yuan, showing a growth of 6.1% year-on-year.
- Based on available ratings, the company has received 3 buy ratings, 1 hold rating and 1 sell rating.
- These recent financial results are comparisons based on values informed by the company’s original disclosures.
A look at Guangzhou Baiyunshan Pharmaceutical Holdings Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., a leading manufacturer and seller of Chinese patent medicine, is positioned for a positive long-term outlook based on its robust Smartkarma Smart Scores. The company excels in value and dividend categories with a top score of 5 in both, indicating strong financial fundamentals and potential for shareholder returns. With solid scores of 4 in growth, resilience, and momentum, Guangzhou Baiyunshan Pharmaceutical Holdings showcases stability, growth potential, and market momentum in the pharmaceutical sector.
Investors looking for a reliable and promising pharmaceutical investment may find Guangzhou Baiyunshan Pharmaceutical Holdings an attractive option, given its high Smartkarma Smart Scores across key indicators. The company’s diverse business activities in manufacturing, wholesaling, retailing, and international trade of pharmaceutical products position it well for continued success and growth in the industry, supported by its strong performance in value, dividend, growth, resilience, and momentum metrics.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
